Lung Cancer Therapeutics Market Trends, Growth, Opportunities, Analysis and Forecast to 2030 | MRFR

Lung Cancer Therapeutics Market

Lung Cancer Therapeutics Market is expected to reach value of USD 30.5 Billion by 2030 at 9.11% CAGR during the forecast period 2022-2030.

Lung cancer is a malignant lung tumor characterized by uncontrolled cell growth in lung tissue with symptoms such as coughing, weight loss, and fatigue and chest pain. The two types of lung cancers are small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). The NSCLC type accounts for almost 80% of the total lung cancers. The cure rates for the two types of lung cancers exchange their positions with the SCLC being the most malignant. The cure rates also depend on the stage of cancer detection with rates varying by 55% for first stage to just 1% for stage four

Almost 85% of cases of lung cancer are due to long-term tobacco smoking. Cigarette smoke contains at least 73 known carcinogens. Other factors causing lung cancer are genetic factors and exposure to triggers and carcinogens such as radon gas, asbestos, radioactive materials, second-hand smoke, or air pollution. It has also been demonstrated that passive smokers have a 20–30% increase in risk.

The treatments for lung cancer include surgery, chemotherapy, and radiotherapy with NSCLC responding better to surgery and SCLC usually responding better to chemotherapy and radiotherapy. Notably, smoking is the primary driver for the rising cases of lung cancer. According to World Health Organization (WHO) tobacco kills more than 7 million people each year of which more than 6 million deaths are the result of direct tobacco use. Lung cancer is the leader with a whopping 37% of deaths. Of more concern is the rising rates of lung cancer due to passive smoking.

Other push factors such as, environmental pollution, rising cases of infections, growing rates of early detection and awareness, rising rates of fast growing lung cancer, and reimbursements and growing health insurance are also fuelling the growth of the market.

Key Players

F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Pfizer (US), Merck & Co., Inc. (US), Bristol-Myers Squibb (US), Eli Lilly and Company (US), and Sanofi (France) are some of the prominent players at the forefront of competition in the lung cancer market and are profiled in MRFR Analysis.

Segmentation by Type of Lung Cancer

  1. Non-Small Cell Lung Cancer (NSCLC)
  2. Small Cell Lung Cancer (SCLC)

The first and most fundamental segmentation of the lung cancer therapeutics market is based on the type of lung cancer. Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are the two primary categories. NSCLC accounts for approximately 85% of all lung cancer cases and can be further divided into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. SCLC, while less common, is an aggressive and fast-growing form of lung cancer. Therapeutic approaches vary significantly between these two categories, highlighting the importance of this initial segmentation.

Segmentation by Treatment Modality

  1. Surgery
  2. Radiation Therapy
  3. Chemotherapy
  4. Targeted Therapy
  5. Immunotherapy

The next crucial segmentation is based on the treatment modality employed to combat lung cancer. Each modality plays a unique role in the management and treatment of the disease. Surgery involves the removal of the tumor and affected tissue, while radiation therapy uses high-energy rays to target and destroy cancer cells. Chemotherapy utilizes drugs to kill cancer cells throughout the body, often as a systemic treatment. Targeted therapy focuses on specific molecular changes within cancer cells, while immunotherapy harnesses the body's immune system to fight cancer. The choice of treatment modality depends on the type and stage of the cancer, as well as the patient's overall health.

Segmentation by Stage

  1. Stage I
  2. Stage II
  3. Stage III
  4. Stage IV

The stage at which lung cancer is diagnosed significantly impacts treatment decisions. The segmentation based on cancer stage is essential, as it helps determine the extent of the disease and the appropriate therapeutic approach. Stage I and II are localized forms of the disease, with the cancer confined to the lung or nearby lymph nodes. In these early stages, surgery and localized treatments like radiation therapy are often the primary options. Stage III lung cancer has spread to the lymph nodes in the middle of the chest, requiring a more extensive treatment approach. Stage IV, the most advanced stage, indicates that the cancer has spread to distant organs. Treatment at this stage is often palliative, focusing on extending the patient's life and improving quality of life.

Segmentation by Geography

  1. North America
  2. Europe
  3. Asia-Pacific
  4. Latin America
  5. Middle East and Africa

The prevalence and management of lung cancer can vary significantly based on geography. Therefore, segmentation by geographical regions is crucial in understanding market dynamics and patient needs. North America and Europe have well-established healthcare systems, leading to a higher prevalence of lung cancer cases and access to advanced therapeutics. In contrast, Asia-Pacific, Latin America, and the Middle East and Africa face unique challenges related to lung cancer therapeutics, including differences in healthcare infrastructure and regional variations in lung cancer subtypes.

About Market Research Future

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 646 845 9312

Email: sales@marketresearchfuture.com

Comments

Post a Comment

Popular posts from this blog

Nanobody Market Expected to Reach 2.94 billion by 2032, Driven by Superior Targeting and Efficacy

  According to MRFR analysis, the global  nanobody market  is expected to register a CAGR of 17.88% from 2023 to 2032 and hold a value of over USD 2.94 billion by 2032 In recent years, the field of biotechnology has witnessed a transformative breakthrough with the advent of nanobodies and Nanobody technology. Nanobodies, also known as VHH antibodies or single-domain antibodies, are small antigen-binding fragments derived from camelid heavy-chain antibodies. Their unique properties have positioned them as powerful tools in various applications, ranging from therapeutic drug development to diagnostics and imaging. Nanobody technology harnesses the potential of these small, robust antibody fragments. Unlike traditional antibodies, nanobodies are compact, stable, and exhibit superior tissue penetration, making them ideal candidates for therapeutic interventions. Their single-domain structure allows for precise targeting of specific antigens, minimizing off-target effects and ...
Read more

US Physician Groups Market Growth with a CAGR of 5.80% to Reach USD 524.1 Billion by 2032

  The  US Physician Groups Market  is expected to reach USD 524.1 Billion by 2032 at 5.80% CAGR during the forecast period 2023-2032. The US Physician Groups market is a dynamic and essential component of the country's healthcare system, comprising a diverse range of medical professionals dedicated to providing primary care services. Among these healthcare providers, the role of the family physician stands out prominently. Family doctors play a pivotal role in delivering comprehensive healthcare to individuals and families, acting as primary points of contact for a wide array of medical concerns. Physician groups in the United States have evolved to meet the growing demand for accessible and personalized healthcare. The emphasis on preventive care and holistic well-being has elevated the significance of family physicians within these groups. These healthcare professionals are trained to address a broad spectrum of medical issues, from routine check-ups to managi...
Read more

Wound Dressings Devices Market, Projected to Grow at a CAGR of 5% and Reach USD 11.63 Billion by 2032

The  Wound Dressings Devices Market  is expected to reach USD 11.63 Billion by 2032 at 5 % CAGR during the forecast period 2023-2032. The global Wound Dressings Devices Market is experiencing significant growth, driven by the increasing prevalence of chronic wounds and a rising aging population. Wound dressings play a crucial role in wound care, promoting healing and preventing infections. As the demand for advanced wound care solutions continues to rise, the market for wound dressing devices is expected to witness steady expansion. Wound dressings  are essential components in the management of various types of wounds, including surgical wounds, diabetic ulcers, and traumatic injuries. The emphasis on effective wound care has led to the development of innovative dressing materials and devices that accelerate the healing process. These devices not only provide a protective barrier against external contaminants but also create an optimal environment for tissue regeneration....
Read more